Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Understanding what makes up a financial plan is essential for effective management. Discover the key aspects that contribute to success.
22,656 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Offerpad rolls out two internal AI platforms, SCOUT and HENRY, as the company pursues 1,000 quarterly home transactio...
As AI brings new pricing for memory, Micron stands at the crossroads of momentum and valuation. This guide breaks dow...
Friday marks the first triple witching of 2026 as Iran tensions flare, prompting investors to brace for volatile move...
Mara Holdings and Riot Platforms fell Friday as higher energy costs collide with investors' questions about AI-driven...
Regulators deliver a landmark clarification for crypto assets, signaling non-securities for most tokens. But the fram...
Apple posted a record iPhone quarter and Meta pushed ad revenue higher, but each faces starkly different bets on AI a...
AI’s endless appetite for compute and memory is shifting demand away from PCs. Prices rise, supply tightens, and inve...
A headline like OpenAI Just Became Broadcom's New Chip Customer signals a dramatic turn in AI hardware. This article ...
Century 21 Chief Executive Mike Miedler says recruiting more Latino agents is crucial to serving the majority of futu...
A new ETF focused on CTAs began trading this week, giving U.S. investors direct exposure to trend-following across mu...
Base, the Coinbase-backed Ethereum Layer 2, is shifting from optimistic rollups to a zero-knowledge-based finality sy...